Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New ...
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
在传统的HIV预防方法中,使用抗病毒药物通常需要每日服用,这不仅增加了患者的用药负担,也降低了患者每日坚持服药的依从性。以lenacapavir为代表的长效疗法,将可能为用户提供更为便利的选择。这种疗法通过每年肌肉注射的方式来维持HIV的抑制效果。一 ...
Lenacapavir是一种“first-in-class”长效HIV病毒衣壳抑制剂,可以干扰HIV病毒衣壳蛋白的组装和拆卸,在病毒生命周期的多个阶段发挥作用。它已经获得美国FDA授予的突破性疗法认定,用于HIV病毒感染暴露前预防。2024年,《科学 ...
2 天
Barchart on MSNGilead Sciences - Leader in HIV MedicinesYour FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
来自吉利德科学公司(Gilead Sciences)的药物研究人员宣布,他们开发的 艾滋病 毒(HIV)预防药物来那卡帕韦(lenacapavir)的新配方使其在人体内存留长达一年的时间。在发表在 Lancet 杂志上的论文中,他们描述了他们如何将这种新配方注射到几名没有感染HIV的志愿者身上,并对他们进行了长达一年的测试,以及他们在这一过程中发现了什么。
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果